MRC1 and Lynch syndrome: We have previously tested the Promega MSI assay in a small cohort of Lynch syndrome-associated urothelial cancers and found only 23% of the tumors to be MSI-H while 90% had immunohistochemical loss of MMR proteins (2), suggesting that MSI analysis of urothelial cancers may not be a suitable screen for Lynch syndrome.